Evidence map›Paper›PMID 37296868›Full record

ArticleCancers2023

The Prognostic Impact of ABO Blood Group in Hepatocellular Carcinoma Following Hepatectomy.

Masaki Kaibori, Kengo Yoshii, Kosuke Matsui, Hideyuki Matsushima, Hisashi Kosaka, Hidekazu Yamamoto, Takayoshi Nakajima, Kazunori Aoi, Takashi Yamaguchi, Katsunori Yoshida and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Masaki KaiboriDepartment of Surgery, Kansai Medical University, Hirakata 573-1010, Japan.ORCID 0000-0002-0577-3921
Kengo YoshiiDepartment of Mathematics and Statistics in Medical Sciences, Kyoto Prefectural University of Medicine, Kyoto 606-0823, Japan.
Kosuke MatsuiDepartment of Surgery, Kansai Medical University, Hirakata 573-1010, Japan.
Hideyuki MatsushimaDepartment of Surgery, Kansai Medical University, Hirakata 573-1010, Japan.
Hisashi KosakaDepartment of Surgery, Kansai Medical University, Hirakata 573-1010, Japan.ORCID 0000-0002-2926-9973
Hidekazu YamamotoDepartment of Surgery, Kansai Medical University, Hirakata 573-1010, Japan.
Takayoshi NakajimaDepartment of Surgery, Kansai Medical University, Hirakata 573-1010, Japan.
Kazunori AoiDepartment of Gastroenterology and Hepatology, Kansai Medical University, Hirakata 573-1010, Japan.
Takashi YamaguchiDepartment of Gastroenterology and Hepatology, Kansai Medical University, Hirakata 573-1010, Japan.ORCID 0000-0003-0557-4321
Katsunori YoshidaDepartment of Gastroenterology and Hepatology, Kansai Medical University, Hirakata 573-1010, Japan.
Mitsugu SekimotoDepartment of Surgery, Kansai Medical University, Hirakata 573-1010, Japan.ORCID 0000-0003-2184-538X
Kansai Medical University · JPKyoto Prefectural University of Medicine · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background/purposeThe effect of the ABO blood group on the survival of patients with hepatocellular carcinoma (HCC) is unclear. The aim of the present study is to determine the prognostic impact of ABO blood types on the survival of a Japanese population of patients with HCC who underwent surgical resection.

methodsPatients with HCC (

resultsIn the study cohort, 173 (36.0%), 133 (27.7%), 131 (27.3%), and 43 (9.0%) of participants had Type A, O, B, and AB, respectively. Type A and non-type A patients were successfully matched based on liver function and tumor characteristics. Recurrence-free survival (RFS; hazard ratio [HR] 0.75, 95% confidence interval [Cl] 0.58-0.98,

conclusionABO blood type may have a prognostic impact on patients with HCC after hepatectomy. Blood type A is an independent unfavorable prognostic factor for recurrence-free and overall survival (RFS and OS) after hepatectomy.

Indexed as

ABO blood grouphepatectomyhepatocellular carcinomaJapanese patientslong-term outcomesnon-type Apropensity score matchingrecurrencerisk factortype A

Identifiers

PMID37296868
PMCPMC10251914
OpenAlexW4378223712

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.